From: Asthma and COPD in cystic fibrosis intron-8 5T carriers. A population-based study
Polythymidine | 9T/9T | 7T/9T | 7T/7T | 6T/7T | 5T/9T | 5T/7T | 5T/5T | 9T/9T | 7T/9T | 7T/7T | 5T/9T | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Expected exon-9 skipping, % | 7 | 13 | 18 | ≥18 | 43 | 48 | 78 | - | - | - | - | |
F508del heterozygosity | yes | yes | yes | yes | P-value | |||||||
Women / Men | 44 / 39 | 841 / 699 | 3,818 / 3,087 | 2 / 2 | 22 / 18 | 171 / 137 | 1 / 1 | 13 / 10 | 127 / 90 | 4 / 1 | 2 / 2 | 0.99 |
Genotype frequency, % | 0.9 | 16.9 | 75.6 | 0.0 | 0.4 | 3.4 | 0.0 | 0.3 | 2.4 | 0.1 | 0.0 | |
Smoking before study entry, packyears* | 16 ± 2.1 | 16 ± 0.5 | 15 ± 0.2 | 13 ± 10 | 18 ± 3.0 | 14 ± 1.1 | 8.4 ± 12 | 13 ± 4.0 | 14 ± 1.3 | 18 ± 10 | 14 ± 10 | 0.81 |
Age at study entry, years | 46 ± 1.4 | 47 ± 0.3 | 47 ± 0.2 | 46 ± 6.3 | 47 ± 2.0 | 46 ± 0.7 | 39 ± 8.9 | 48 ± 2.6 | 48 ± 0.9 | 41 ± 5.6 | 46 ± 6.3 | 0.63 |
FEV1 at study entry, %pred. | 87 ± 1.9 | 90 ± 0.4 | 90 ± 0.2 | 83 ± 8.8 | 96 ± 2.8 | 90 ± 1.0 | 84 ± 12 | 94 ± 3.7 | 89 ± 1.2 | 84 ± 7.9 | 101 ± 8.8 | 0.24 |
Smoking during follow-up, g/day† | 9.0 ± 1.1 | 8.8 ± 0.3 | 8.9 ± 0.1 | 11 ± 5.0 | 8.1 ± 1.6 | 7.5 ± 0.6 | 6.3 ± 7.1 | 7.9 ± 2.1 | 7.1 ± 0.7 | 8.0 ± 4.5 | 8.0 ± 5.0 | 0.24 |
Follow-up, years | 23 ± 0.14 | 23 ± 0.03 | 23 ± 0.02 | 23 ± 0.66 | 23 ± 0.21 | 23 ± 0.08 | 24 ± 0.93 | 23 ± 0.27 | 23 ± 0.09 | 24 ± 0.59 | 24 ± 0.66 | 0.97 |